Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 5/20 | 0.48 |
| ▸ | HINT1 | P49773 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12878136 | 1.00 | NT5E (0.56) | NT5EPOLBTAS1R3TAS1R1IMPDH2 | |
| SCHEMBL18061808 | 1.00 | NT5E (0.56) | NT5EPOLBTAS1R3TAS1R1IMPDH2 | |
| SCHEMBL12799371 | 1.00 | NT5E (0.56) | NT5EPOLBTAS1R3TAS1R1IMPDH2 | |
| SCHEMBL12849790 | 1.00 | NT5E (0.56) | NT5EPOLBTAS1R3TAS1R1IMPDH2 | |
| SCHEMBL12799375 | 0.93 | TGM2 (0.58) | NT5EPOLBTAS1R3TAS1R1IMPDH2 | |
| SCHEMBL12878145 | 0.93 | TGM2 (0.58) | NT5EPOLBTAS1R3TAS1R1IMPDH2 | |
| SCHEMBL12849789 | 0.93 | TGM2 (0.58) | NT5EPOLBTAS1R3TAS1R1IMPDH2 | |
| SCHEMBL18061560 | 0.93 | TGM2 (0.58) | NT5EPOLBTAS1R3TAS1R1IMPDH2 | |
| Psi-352666 SCHEMBL12878134 | 0.92 | TGM2 (0.57) | NT5EPOLBTAS1R3TAS1R1TGM2 | |
| Psi-352666 SCHEMBL18061810 | 0.92 | TGM2 (0.57) | NT5EPOLBTAS1R3TAS1R1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091050-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | Atea Pharmaceuticals, Inc. (US) | 2026-04-02 | — | — | US | disclosed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260035404-A1 | ADVANTAGEOUS MORPHIC FORM OF AT-527 HEMI-SULFATE SALT | Atea Pharmaceuticals, Inc. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12458656-B2 | Advantageous anti-HCV combination therapy | Atea Pharmaceuticals, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250281520-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | Atea Pharmaceuticals, Inc. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250109163-A1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | Atea Pharmaceuticals, Inc. (US) | 2025-04-03 | — | — | US | disclosed |
| EP-3897668-B1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA PHARMACEUTICALS INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12226429-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2025-02-18 | — | — | US | disclosed |
| EP-3577124-B1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | ATEA PHARMACEUTICALS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4450129-A2 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | ATEA Pharmaceuticals, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20180215776-A1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | Atea Pharmaceuticals, Inc. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215776-A1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | Atea Pharmaceuticals, Inc. (US) | 2018-08-02 | — | — | US | disclosed |
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10000523-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000523-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215776-A1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | HAVCR2, HCCS, SLC10A1 | NT5E 711/4885POLB 788/4885TAS1R3 3868/4885 |
| US-20250109163-A1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | HAVCR2, HCCS, SLC10A1 | NT5E 711/4885POLB 788/4885TAS1R3 3868/4885 |
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | NT5E 45/4885POLB 163/4885TAS1R3 4117/4885 |
| US-12458656-B2 | Advantageous anti-HCV combination therapy | HAVCR2, SLC10A1, EIF2AK2 | NT5E 4414/4885POLB 2256/4885TAS1R3 4358/4885 |
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | NT5E 117/4885POLB 226/4885TAS1R3 2822/4885 |
| US-12226429-B2 | Highly active compounds against COVID-19 | PNP, MTAP, ACE2 | NT5E 28/4885POLB 228/4885TAS1R3 3148/4885 |
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | NT5E 62/4885POLB 81/4885TAS1R3 4556/4885 |
| US-10000523-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | NT5E 49/4885POLB 130/4885TAS1R3 4133/4885 |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | NT5E 52/4885POLB 89/4885TAS1R3 4546/4885 |
| US-20260035404-A1 | ADVANTAGEOUS MORPHIC FORM OF AT-527 HEMI-SULFATE SALT | ATIC, SLC11A2, SLC7A1 | NT5E 4128/4885POLB 3821/4885TAS1R3 1083/4885 |
| US-20250281520-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | HAVCR2, SLC10A1, EIF2AK2 | NT5E 4414/4885POLB 2256/4885TAS1R3 4358/4885 |
| US-20260091050-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | SLC10A1, SLC10A2, STAT3 | NT5E 2405/4885POLB 3097/4885TAS1R3 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.